- 全部删除
- 您的购物车当前为空
PCO371 (2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-) 是口服具有活性的甲状旁腺激素受体 1 的完全激动剂,对 PTHR2 无作用
为众多的药物研发团队赋能,
让新药发现更简单!
PCO371 (2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-) 是口服具有活性的甲状旁腺激素受体 1 的完全激动剂,对 PTHR2 无作用
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 428 | In stock | |
5 mg | ¥ 793 | In stock | |
10 mg | ¥ 1,290 | In stock | |
25 mg | ¥ 2,120 | In stock | |
50 mg | ¥ 3,480 | In stock | |
100 mg | ¥ 4,980 | In stock | |
1 mL x 10 mM (in DMSO) | ¥ 1,130 | In stock |
PCO371 相关产品
产品描述 | PCO371 (2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl-) is an orally active full agonist of parathyroid hormone receptor 1. It has no effect on PTH type 2 receptor. |
靶点活性 | PTHR1 (COS-7 cells):2.4 μM (EC50), hPTHR1-delNT (COS-7 cells):17 μM (EC50), LLC-PK1 cells:4.1 mM (EC50) |
体外活性 | 在表达hPTHR1的COS-7细胞中,PCO371引发cAMP产生(EC50:2.4μM)。在转染有hPTHR1-delNT的COS-7细胞中,2.5μM的PCO371同样能增强磷脂酶C活性(EC50,17μM)[1]。 |
别名 | 2,4-Imidazolidinedione, 1-(3,5-dimethyl-4-(2-((4-oxo-2-(4-(trifluoromethoxy)phenyl)-1,3,8-triazaspiro(4.5)dec-1-en-8-yl)sulfonyl)ethyl)phenyl)-5,5-dimethyl- |
分子量 | 635.65 |
分子式 | C29H32F3N5O6S |
CAS No. | 1613373-33-3 |
Smiles | Cc1cc(cc(C)c1CCS(=O)(=O)N1CCC2(CC1)N=C(NC2=O)c1ccc(OC(F)(F)F)cc1)N1C(=O)NC(=O)C1(C)C |
密度 | 1.47 g/cm3 (Predicted) |
存储 | keep away from direct sunlight,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 120 mg/mL (188.78 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容